B
Bull
Bull · 25%ELVN
$25.90
Precio del escenario
$57.860
-2.523 (-4.36%)Al cierre
Loading chart…
- High
- 61.180
- Open
- 60.400
- VWAP
- 58.92
- Vol
- 584.98K
- Mkt Cap
- 1.10B
- Low
- 57.730
- Amount
- 34.47M
- EV/EBITDA, TTM
- 0.00
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.
AI analysis of Enliven Therapeutics Inc (ELVN)
holdEnliven Therapeutics is currently trading at $57.86, which is below the average analyst price target of $75, indicating potential upside. However, the RSI is at 31.61, suggesting the stock is oversold, and the company has reported consistent net losses, with Q2 EPS at -0.49, missing expectations. The main risk is the ongoing negative earnings trend, with a projected net income loss of approximately $32 million for Q2 2026.
Métricas de valoración
The current forward P/E ratio for Enliven Therapeutics Inc (ELVN) is 0.00, compared to its 5-year average forward P/E of -9.29.
Alphio AI Price Scenarios for ELVN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ELVN
Cronología de eventos
Noticias
8.508-05seekingalphaEnliven Therapeutics Q2 Earnings Miss Expectations
8.508-02NASDAQ.COMFive Biotech Stocks Investors Should Watch
2.007-17NASDAQ.COMBiotech Stocks Reach 52-Week Highs Amid Positive Developments
5.006-27NASDAQ.COMEnliven Therapeutics Director Sells Shares Amid Rising Investor Sentiment
5.006-27FoolEnliven Therapeutics Director Sells Shares
ELVN FAQ — answered by Alphio AI
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Enliven Therapeutics is currently trading at $57.86, which is below the average analyst price target of $75, indicating potential upside. However, the RSI is at 31.61, suggesting the stock is oversold, and the company has reported consistent net losses, with Q2 EPS at -0.49, missing expectations. The main risk is the ongoing negative earnings trend, with a projected net income loss of approximately $32 million for Q2 2026.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.